Recombinant toxins for cancer treatment.
Recombinant toxins target cell surface receptors and antigens on tumor cells. They kill by mechanisms different from conventional chemotherapy, so that cross resistance to conventional chemotherapeutic agents should not be a problem. Furthermore, they are not mutagens and should not induce secondary malignancies or accelerate progression of benign malignancies. They can be mass-produced cheaply in bacteria as homogeneous proteins. Either growth factor-toxin fusions or antibody-toxin fusions can be chosen, depending on the cellular target.
Pastan
I
I
Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
FitzGerald
D
D
D036002:ADP Ribose Transferases; D000951:Antigens, Neoplasm / Q000378:metabolism; D001427:Bacterial Toxins; D066246:ErbB Receptors / Q000378:metabolism; D005098:Exotoxins / Q000008:administration & dosage; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases; D011971:Receptors, Immunologic / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D019947:Receptors, Interleukin-6; D011993:Recombinant Fusion Proteins; D014118:Toxins, Biological / Q000008:administration & dosage*; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000951:Antigens, Neoplasm; D001427:Bacterial Toxins; D066246:ErbB Receptors; D005098:Exotoxins; D000922:Immunotoxins; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2; D019947:Receptors, Interleukin-6; D011993:Recombinant Fusion Proteins; D014118:Toxins, Biological; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A